Transgene Biotek Limited.

As of June 30, 2026, Transgene Biotek Limited. carries a market capitalization of 234.89M, placing it among publicly traded companies globally. Its enterprise value stands at 234.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Transgene Biotek Limited. has 75.77M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 105.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 234.89M versus a market cap of 234.89M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

As of the close on October 23, 2026, Transgene Biotek Limited.'s stock has declined approximately 37.65% over the past 52 weeks. The 50-day moving average sits at 2.68, while the 200-day moving average is 2.76.

Over the twelve months ended June 30, 2026, Transgene Biotek Limited. generated 2.22M in revenue and converted that into -16.08M in net income, yielding earnings per share of -0.21. EBITDA reached -4.63M, while operating income came in at -6.54M.

Over the twelve months ended June 30, 2026, Transgene Biotek Limited. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -294.86 and net profit margin of -725.07 provide insight into operational efficiency.